AbCellera Biologics (NASDAQ:ABCL – Get Free Report) had its price objective hoisted by stock analysts at Stifel Nicolaus from $9.00 to $14.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus‘s price target would indicate a potential upside of 12.00% from the company’s previous close.
Several other brokerages also recently weighed in on ABCL. The Goldman Sachs Group initiated coverage on shares of AbCellera Biologics in a research note on Thursday, September 24th. They set a “neutral” rating and a $13.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of AbCellera Biologics in a report on Thursday, October 15th. Jefferies Financial Group began coverage on AbCellera Biologics in a research report on Friday, October 30th. They issued a “buy” rating and a $21.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on AbCellera Biologics in a research note on Tuesday, September 29th. They set an “overweight” rating and a $17.00 price objective for the company. Finally, UBS Group initiated coverage on AbCellera Biologics in a research report on Monday, October 12th. They set a “buy” rating and a $18.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, AbCellera Biologics currently has an average rating of “Moderate Buy” and an average price target of $16.33.
View Our Latest Stock Analysis on ABCL
AbCellera Biologics Price Performance
Shares of NASDAQ:ABCL opened at $12.50 on Tuesday. The stock has a market cap of $3.83 billion, a P/E ratio of -23.15 and a beta of 1.59. The firm has a fifty day moving average price of $12.30 and a 200 day moving average price of $7.08. AbCellera Biologics has a 1-year low of $2.74 and a 1-year high of $15.02.
AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. The company had revenue of $10.64 million for the quarter, compared to the consensus estimate of $8.41 million. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. During the same period last year, the firm posted ($0.19) EPS. Sell-side analysts expect that AbCellera Biologics will post -0.69 EPS for the current fiscal year.
Hedge Funds Weigh In On AbCellera Biologics
Several institutional investors have recently bought and sold shares of the company. Blume Capital Management Inc. lifted its stake in shares of AbCellera Biologics by 22.7% in the 3rd quarter. Blume Capital Management Inc. now owns 5,501 shares of the company’s stock worth $80,000 after acquiring an additional 1,017 shares during the period. AssuredPartners Investment Advisors LLC purchased a new stake in shares of AbCellera Biologics in the second quarter valued at about $80,000. ProShare Advisors LLC boosted its holdings in shares of AbCellera Biologics by 12.2% in the third quarter. ProShare Advisors LLC now owns 11,235 shares of the company’s stock valued at $164,000 after acquiring an additional 1,224 shares in the last quarter. Allworth Financial LP acquired a new position in shares of AbCellera Biologics during the second quarter worth about $91,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of AbCellera Biologics during the first quarter worth about $46,000. 61.42% of the stock is owned by institutional investors and hedge funds.
AbCellera Biologics News Summary
Here are the key news stories impacting AbCellera Biologics this week:
- Positive Sentiment: AbCellera reported a Q3 loss of $0.13 per share, narrower than the roughly $0.17–$0.18 loss analysts expected and the $0.19 loss a year earlier. Revenue of $10.64 million also topped the $8.41 million consensus estimate, giving investors evidence of better-than-expected results. Zacks Q3 earnings report
- Negative Sentiment: The earnings beat does not yet resolve profitability concerns: ABCL still reported a quarterly loss, with a negative net margin and negative return on equity. Continued losses could temper the positive reaction to the revenue and EPS surprise. MarketBeat earnings report
AbCellera Biologics Company Profile
AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease.
The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Founded in 2012, AbCellera has collaborated with global partners, including Eli Lilly, on antibody treatments for COVID-19.
See Also
- Five stocks we like better than AbCellera Biologics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
